Latest Articles
Browse a selection of ImaginAb press and news below.
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc.
Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets
Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets.
ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent
Collaboration to explore novel radiochemistry manufacture of ImaginAb’s Phase II clinical asset.
ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology
Under the terms of the agreement, ImaginAb’s CD8 ImmunoPET technology will be used in AstraZeneca’s clinical trials in North America and Europe to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET.
ImaginAb Initiates Phase II Clinical Trial at Penn Medicine
ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Penn Medicine in Philadelphia, PA. Penn Medicine is one of the world’s leading academic medical centers.
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology
ImaginAb, Inc., signs multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited (Takeda) focused on furthering the clinical development of ImaginAb’s CD8 ImmunoPET technology.